• 1
    European Helicobacter Pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41: 813.
  • 2
    Howden C & Hunt RH. Guidelines for the management of Helicobacter pylori. Am J Gastroenterol 1998; 93: 23308.
    Direct Link:
  • 3
    Lam SK & Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998; 13: 112.
  • 4
    Hunt RH, Fallone CA, Thomson ABR. Canadian Helicobacter pylori Consensus Conference update: infections in adults. Can J Gastroenterol 1999; 13.
  • 5
    Coelho LG, Leon-Barua R, Quigley EM. Latin-American Consensus Conference on Helicobacter pylori infection. Latin-American National Gastroenterological Societies affiliated with the Inter-American Association of Gastroenterology (AIGE). Am J Gastroenterol 2000; 95(10): 268891.
    Direct Link:
  • 6
    Nakajima S, Graham DY, Hattori T , et al. Strategy for treatment of Helicobacter pylori infection in adults. I. Updated indications for test and eradication therapy suggested in 2000. Curr Pharm Des 2000; 6(15): 150314.
  • 7
    Breuer T, Goodman KJ, Malaty HM , et al. How do clinicians practicing in the U.S. manage Helicobacter pylori-related gastrointestinal diseases? A comparison of primary care and specialist physicians. Am J Gastroenterol 1998; 93(4): 55361.
    Direct Link:
  • 8
    Breuer T, Sudhop T, Goodman KJ , et al. How do practicing clinicians manage Helicobacter pylori-related gastrointestinal diseases in Germany? A survey of gastroenterologists and family practitioners. Helicobacter 1998; 3(1): 18.
  • 9
    Labenz J & Malfertheiner P. Helicobacter pylori — when and how do gastroenterologists treat themselves? A clinical and practical survey. Dtsch Med Wochenschr 1997; 122(20): 63742.
  • 10
    Drumm B, Koletzko S, Oderda G. Helicobacter pylori infection in children: a consensus statement. J Pediatr Gastroenterol Nutr 2000; 30: 20713.
  • 11
    Heaney A, Collins JSA, Watson RGP , et al. A prospective randomized trial of a ‘test and treat’ policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic. Gut 1999; 45: 18690.
  • 12
    Jones R, Tait C, Sladen G , et al. A trial of a test-and-treat strategy for Helicobacter pylori positive dyspeptic patients in general practice. Int J Clin Pract 1999; 53: 4136.
  • 13
    Lassen AM, Pedersen FM, Bytzer P , et al. Helicobacter pylori ‘Test and eradicate’ or prompt endoscopy for management of dyspeptic patients. A randomized, controlled trial with one year follow-up. Lancet 2000; 356: 45560.
  • 14
    Moayyedi P, Feltbower R, Brown J , et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group. Lancet 2000; 355(9216): 16659.
  • 15
    Delaney BC, Wilson S, Roalfe A , et al. Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: a randomised controlled trial in primary care. Lancet 2000; 356(9246): 19659.
  • 16
    Asante MA, Mendall M, Patel P , et al. A randomized trial of endoscopy vs no endoscopy in the management of seronegative Helicobacter pylori dyspepsia. Eur J Gastroenterol Hepatol 1998; 10(12): 9839.
  • 17
    Di Mario F, Molaro M, Dal Bó N , et al. Does Helicobacter pylori infection eradication modify peptic ulcer prevalence? Gastroenterology 1998; 114(4): A104A104(Abstract).
  • 18
    Leodolter A, Dominguez-Muñoz JE, Von Arnim U. Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting. Am J Gastoenterol 1999; 94: 21004.
    Direct Link:
  • 19
    Vaira D, Malfertheiner P, Mégraud F , et al. Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. Lancet 1999; 354: 303.
  • 20
    Stanghellini V, Anti M, Bianchi Porro G , et al. Risk indicators of organic diseases in uninvestigated dyspepsia: a one-week survey in 246 Italian endoscopy units. Eur J Gastroenterol Hepatol 1999; 11: 112934.
  • 21
    Duggan A, Elliott C, Logan R. Testing for Helicobacter pylori infection: validation and diagnostic yield of a near patient test in primary care. Br Med J 1999; 19: 12369.
  • 22
    Wong BCY, Wong W-M, Tang VSY , et al. An evaluation of whole blood testing for Helicobacter pylori infection in the Chinese population. Aliment Pharmacol Ther 2000; 14: 3315.
  • 23
    Megraud F, Burette A, Glupczynski Y , et al. Comparison of tests for assessment of Helicobacter pylori eradication: results of a multi-centre study using centralized facility testing. Eur J Gastroenterol Hepatol 2000; 12(6): 62933.
  • 24
    Vaira D & Vakil N. Blood, urine, stool, breath, money, and Helicobacter pylori. Gut 2001; 48(3): 2879.
  • 25
    Vaira D, Malfertheiner P, Megraud F , et al. Noninvasive antigen-based assay for assessing Helicobacter pylori eradication: a European multicenter study. The European Helicobacter pylori HpSA Study Group. Am J Gastroenterol 2000; 95(4): 9259.
    Direct Link:
  • 26
    Fischbach W. MALT Lymphome des Magens. Dtsch Wschr 1999; 124: 11427.
  • 27
    Morgner A, Lehn N, Andersen LP , et al. Helicobacter heilmanii-associated primary gastric low grade MALT lymphoma: complete remission after curing infection. Gastroenterology 2000; 118: 8218.
  • 28
    Neubauer A, Thiede C, Morgner A , et al. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa associated lymphoid tissue lymphoma. J Natl Cancer Inst 1997; 89: 13505.
  • 29
    Sackmann M, Morgner A, Rudolph B , et al. Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT lymphoma Study Group. Gastroenterology 1997; 113: 108790.
  • 30
    Ruskone-Fourmestraux A, Lavergne A, Aegerter PH , et al. Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut 2001; 48(3): 297303.DOI: 10.1136/gut.48.3.297
  • 31
    Valle J, Kekki M, Sipponen P , et al. Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. Scand J Gastroenterol 1996; 31(6): 54650.
  • 32
    Sung JJY, Lin SR, Ching JYL , et al. Atrophy and intestinal metaplasia one year after cure of Helicobacter pylori infection: a prospective, randomized study. Gastroenterology 2000; 119: 714.
  • 33
    El-Omar E, Oien K, Murray LS , et al. Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. Gastroenterology 2000; 118: 2230.
  • 34
    Brenner H, Bode G, Boeing H. Helicobacter pylori infection among offspring of patients with stomach cancer. Gastroenterology 2000; 118: 315.
  • 35
    Parsonnet J, Harris RA, Hack HM , et al. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet 1996; 348: 1504.
  • 36
    El-Omar E, Carrington M, Chow W-H , et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398402.DOI: 10.1038/35006081
  • 37
    Tepes B, Kavcic B, Zaletel L , et al. Two to four year histological follow up of gastric mucosa after Helicobacter pylori eradication. J Pathol 1999; 188: 249.
  • 38
    Moayyedi P, Soo S, Deeks J , et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Br Med J 2000; 321: 65964.
  • 39
    McCarthy C, Pachett S, Collins RM , et al. Long-term prospective study of Helicobacter pylori in non-ulcer dyspepsia. Dig Dis Sci 1995; 40: 1149.
  • 40
    McColl KEL, Murray L, El-Omar E , et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with non-ulcer dyspepsia. N Engl J Med 1998; 339: 186974.
  • 41
    Malferheiner P, Fischbach W, Layer P , et al. Elan study proves symptomatic benefit of Helicobacter pylori eradication in functional dyspepsia. Gastroenterology 2000; (A)118: 24212421.
  • 42
    Greenberg PD & Cello JP. Lack of effect of treatment for Helicobacter pylori on symptoms of non-ulcer dyspepsia. Arch Intern Med 1999; 159: 22838.
  • 43
    Blum AL, Talley NJ, O'Morain C , et al. Lack of effect of treating Helicobacter pylori infection in patients with non-ulcer dyspepsia. N Engl J Med 1998; 339: 187581.
  • 44
    Talley NJ, Janssens J, Lauritsen K , et al. Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months’ follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. Br Med J 1999; 318(7187): 8337.
  • 45
    Talley NJ, Meineche-Schmidt V, Pare P , et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998; 12(11): 105565.
  • 46
    Blum AL, Arnold R, Stolte M , et al. Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group. Gut 2000; 47(4): 47380.
  • 47
    Tefera S, Hatlebakk JG, Berstad A. The effect of Helicobacter pylori eradication on gastro-oesophageal reflux. Aliment Pharmacol Ther 1999; 13: 91520.
  • 48
    Peters FT, Kuipers EJ, Ganesh S , et al. The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy. Aliment Pharmacol Ther 1999; 13(7): 9216.DOI: 10.1046/j.1365-2036.1999.00556.x
  • 49
    O'Connor HJ. Review article: Helicobacter pylori and gastro-oesophageal reflux disease — clinical implications and management. Aliment Pharmacol Ther 1999; 13(2): 11727.
  • 50
    Axon AT, Bardhan KD, Moayyedi P , et al. Does eradication of Helicobacter pylori influence the recurrence of symptoms in patients with symptomatic gastro-oesophageal reflux disease? — A randomised double blind study. Gastroenterology 1999; 116(4): A117A117(Abstract).
  • 51
    Malfertheiner P & Gerards C. Helicobacter pylori infection and gastro-oesophageal reflux disease: coincidence or association? Baillieres Best Pract Res Clin Gastroenterol 2000; 14(5): 73141.
  • 52
    El-Serag HB, Sonnenberg A, Jamal MM , et al. Corpus gastritis is protective against reflux oesophagitis. Gut 1999; 45: 1815.
  • 53
    Hamada H, Haruma K, Mihara M , et al. High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther 2000; 14(6): 72935.DOI: 10.1046/j.1365-2036.2000.00758.x
  • 54
    Malfertheiner P, Veldhuyzen van Zanten S, Dent J , et al. Does cure of Helicobacter pylori infection induce heartburn? Gastroenterology 1998; 114(4): A212A212(Abstract).
  • 55
    Kuipers EJ, Lundell L, Klinkenberg-Knoll EC , et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 101822.
  • 56
    Klinkenberg-Knol EC, Nelis F, Dent J , et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118(4): 6619.
  • 57
    Stolte M, Meining A, Schmitz JM , et al. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998; 12: 24753.DOI: 10.1046/j.1365-2036.1998.00310.x
  • 58
    McColl KEL, Murray LS, Gillen D. Omeprazole and accelerated onset of atrophic gastritis. Gastroenterology 2000; 118: 239239.
  • 59
    Lundell L, Miettinen P, Myrcold HE , et al. Lack of effect of acid suppression therapy on gastric atrophy. Gastroenterology 1999; 117: 31926.
  • 60
    Huang J-Q, Lad R, Hunt RH. Role of Helicobacter pylori infection in NSAID-associated gastropathy. In: Hunt RH, Tytgat GN, eds. Helicobacter Pylori — Basic Mechanism to Clinical Cure 2000. Dordrecht: Kluwer Academic Publishers, 2000: 443–52.
  • 61
    Aalykke C, Lauritsen JM, Hallas J , et al. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case-control study. Gastroenterology 1999; 116: 13059.
  • 62
    Chan FK, Sung JY, Chan SC , et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-flammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350: 9759.
  • 63
    Koelz HR, Bolten W, Dragosics B , et al. Primary prophylaxis of NSAID-induced gastroduodenal ulcers and dyspepsia in H. pylori (HP)-infected patients: randomized, double-blind, placebo-controlled treatment of HP infection vs. omeprazole. Gastroenterology 2000; 118: A250A250(Abstract).
  • 64
    Hawkey CJ, Tulassay Z, Szczepanski L , et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Lancet 1998; 352: 101621.
  • 65
    Yeomans ND. New data on healing of nonsteroidal anti- inflammatory drug-associated ulcers and erosions. Omeprazole NSAID Steering Committee. Am J Med 1998; 104(3A): 56S61S.
  • 66
    Bianchi PG, Lazzaroni M, Manzionna G , et al. Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer. Aliment Pharmacol Ther 1998; 12(4): 35560.
  • 67
    Chan FK & Sung JJ. How does Helicobacter pylori infection interact with non-steroidal anti-inflammatory drugs? Baillieres Best Pract Res Clin Gastroenterol 2000; 14(1): 16172.
  • 68
    Chan FK, Sung JY, Suen BY , et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344(13): 96773.
  • 69
    Freston JW. Management of peptic ulcers: emerging issues. World J Surg 2000; 24(3): 2505.
  • 70
    Danesh J, Youngman L, Clark S , et al. Helicobacter pylori and early-onset myocardial infarction: case-control and sibling pair studies. Br Med J 1999; 319: 115762.
  • 71
    Annibale B, Marignani M, Monarca B , et al. Reversal of iron-deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis. Ann Intern Med 1999; 131: 66872.
  • 72
    Gasbarrini A, Franceschi F, Tartaglione R , et al. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 1998; 352(9131): 878878.
  • 73
    Leontiadis GI, Sharma VK, Howden CW. Non-gastrointestinal tract associations of Helicobacter pylori infection. Arch Intern Med 1999; 159(9): 92540.
  • 74
    Gisbert JP, Pajares JM, Valle J. Ranitidine bismuth citrate therapy regimens for treatment of Helicobacter pylori infection: a review. Helicobacter 1999; 4: 5866.DOI: 10.1046/j.1523-5378.1999.09038.x
  • 75
    Pipkin GA, Williamsson R, Wood JR. Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. Aliment Pharmacol Ther 1998; 12: 82337.DOI: 10.1046/j.1365-2036.1998.00405.x
  • 76
    Lind T, Mégraud F, Unge P , et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116: 24853.
  • 77
    Misiewicz JJ, Harris AW, Bardhan KD , et al. One week triple therapy for Helicobacter pylori: a multicenter comparative study. Gut 1997; 41: 7359.
  • 78
    Laheij RJF, Van Rossum LGM, Jansen JBMJ , et al. Evaluation of treatment regimens to cure Helicobacter pylori infection — a meta-analysis. Aliment Pharmacol Ther 1999; 13: 85764.
  • 79
    Unge P. Antimicrobial treatment of H. pylori infection — a pooled efficacy analysis of eradication therapies. Eur J Surg 1998; 164(Suppl.582): 1626.
  • 80
    Pilotto A, Di Mario F, Franceschi M. Treatment of H. pylori infection in elderly subjects. Age Ageing 2000; 29: 1039.
  • 81
    Gisbert JP, Gonzalez L, Calvet X , et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000; 14(10): 131928.DOI: 10.1046/j.1365-2036.2000.00844.x
  • 82
    Tulassay Z, Kryszewski A, Dite P , et al. One-week treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. Eur J Gastroenterol Hepatol 2001; in press.
  • 83
    Mégraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology 1998; 115: 127882.
  • 84
    Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 1998; 115(5): 12727.
  • 85
    Mégraud F & Marshall BJ. How to treat Helicobacter pylori. Gastroenterol Clin North Am 2000; 29(4): 75973.
  • 86
    Parkin DM. Cancer in developing countries. Cancer Surv 1994; 19–20: 51961.
  • 87
    Parsonnet J. When heredity is infectious. Gastroenterology 2000; 118(1): 2224.
  • 88
    Forman D. Helicobacter pylori and gastric cancer: the risk is real. In: Hunt RH, Tytgat GN, eds. Helicobacter Pylori — Basic Mechanism to Clinical Cure 2000. Dordrecht: Kluwer Academic Publishers, 2000: 507–11.
  • 89
    Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80(6): 82741.DOI: 10.1002/(sici)1097-0215(19990315)80:6<827::aid-ijc6>;2-p
  • 90
    Danesh J. Helicobacter pylori and gastric cancer: time for mega-trials? Br J Cancer 1999; 80(7): 9279.
  • 91
    Varis K, Sipponen P, Laxen F , et al. Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Helsinki Gastritis Study Group. Scand J Gastroenterol 2000; 35(9): 9506.
  • 92
    Correa P. Human gastric carcinogenesis: a multistep and multifactorial process — First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52(24): 673540.
  • 93
    El Omar EM, Oien K, El Nujumi A , et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997; 113(1): 1524.
  • 94
    Van Der Hulst RWM, Ten Kate FJW, Rauws EAJ, et al.The relation of cagA and the long-term sequelae of gastritis after successful cure of Helicobacter pylori: a long-term follow-up study. Gastroenterology 1998; 114: A318A318 (Abstract).
  • 95
    Forman D. Lessons from ongoing intervention studies. In: Hunt RH, Tytgat GNJ, eds. Helicobacter Pylori: Basic Mechanisms to Clinical Cure, 1998. Dordrecht: Kluwer Academic Publishers, 1998: 354–60.
  • 96
    El Zimaity HM & Graham DY. Evaluation of gastric mucosal biopsy site and number for identification of Helicobacter pylori or intestinal metaplasia: role of the Sydney System. Hum Pathol 1999; 30(1): 727.
  • 97
    Uemura N & Okamoto S. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer in Japan. Gastroenterol Clin North Am 2000; 29(4): 81927.
  • 98
    Sherman P, Hassall E, Hunt RH , et al. Consensus Conference on the approach to Helicobacter pylori infection in children and adolescents. Can J Gastroenterol 1999; 13: 5539.
  • 99
    Gold B & Goodman K. Helicobacter pylori infection in children: To test or not to test…. What is the evidence? J Pediatr 2000; 136: 7146.
  • 100
    Kalach N, Bergeret M, Benhamou PH , et al. High levels of resistance to metronidazole and clarithromycin in Helicobacter pylori strains in children. J Clin Microbiol 2001; 39(1): 3947.